Royalty Pharma plc
59.05 +0.44 (0.75%)
59.08 +0.06%
- Capitalización de mercado
- $34.12B
- Volumen
- 2.97M
- Próxima fecha de resultados
- Nov 4, 2026
Royalty Pharma plc (RPRX): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →$61,00 – $70,00
mediana $65,50 · 10.92% Potencial alcista
Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $674.1M | n/a | +16.50% |
| EPS | $1,32 | +$0,05 | +15.79% |
Métricas
- Precio de compra
- 58.9
- Ingresos (TTM)
- 2.54B
- Beneficio neto (TTM)
- 812M
- 0.43
- 1.86
- 31.75
- 10.3
- P/B (TTM)
- 3.85
- P/S (TTM)
- 13.45
- Fecha de resultados
- Nov 4, 2026
- Precio de venta
- 59.08
- Volumen
- 2,967,174
- Volumen medio (20D)
- 3,130,059
- Abierto
- 58.66
- Anterior Cerrar
- 58.61
- Rango del día
- 57.75 - 59.55
- Rango de 52 semanas
- 34.63 - 64.38
- analista
- Fuerte<br>Comprar
- Precio objetivo
- 65.5 (10.92%)
- Dividendos
- $0.94 (1.60%)
- Fecha ex dividendo
- Aug 14, 2026
Acerca de Royalty Pharma plc
Ver perfil →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Industria Biotechnology
Sector Healthcare
IPO Fecha Jun 16, 2020
Empleados 100
Bolsa de Valores NasdaqGS
Símbolo bursátil RPRX
Sitio web https://www.royaltypharma.com